Results 11 to 20 of about 50,723 (266)

Surgical menopause in patients with BRCA mutation, the role of hormone therapy

Revista del Hospital Italiano de Buenos Aires, 2023
Introduction: Women with BRCA1/2 (mBRCA) mutation have an increased risk of developing breast (BC) and ovarian (OC) cancer. Bilateral salpingo-oophorectomy (BOS) is associated with an 80% risk reduction for OC and 50% for BC. The recommended age for this
María Alejandra Belardo, Magali L. Galarza Taborda   +1 more
doaj   +1 more source

BRCA Share: A Collection of Clinical BRCA Gene Variants. [PDF]

Human mutation, 2016
As next-generation sequencing increases access to human genetic variation, the challenge of determining clinical significance of variants becomes ever more acute. Germline variants in the BRCA1 and BRCA2 genes can confer substantial lifetime risk of breast and ovarian cancer.
Béroud, Christophe, Letovsky, Stanley I, Braastad, Corey D, Caputo, Sandrine M, Beaudoux, Olivia, Bignon, Yves Jean, Bressac-de Paillerets, Brigitte, Bronner, Myriam, Buell, Crystal M, Collod-Beroud, Gwenaelle, Coulet, Florence, Derive, Nicolas, Divincenzo, Christina, Elzinga, Christopher D, Garrec, Céline, Houdayer, Claude, Karbassi, Izabela, Lizard, Sarab, Love, Angela, Muller, Danièle, Nagan, Narasimhan, Nery, Camille R, Rai, Ghadi, Révillion, Françoise, Salgado, David, Sevenet, Nicolas, Sinilnikova, Olga, Sobol, Hagay, Stoppa-Lyonnet, Dominique, Toulas, Christine, Trautman, Edwin, Vaur, Dominique, Vilquin, Paul, Weymouth, Katelyn S, Willis, Alecia, Eisenberg, Marcia, Strom, Charles M   +36 more
openaire   +5 more sources

Modern interpretation of risk factors in breast cancer of women

Journal of Mind and Medical Sciences, 2022
Breast cancer is a major public health problem, being the most common cancer diagnosed in women and accounting for more than 1 in 10 new diagnoses of cancer each year.
Oana Denisa Bălălău, Răzvan Valentin Scăunașu, Octavian Gabriel Olaru, Anca Silvia Dumitriu, Stana Paunica, Liliana Florina Andronache, Anca Daniela Stănescu   +6 more
doaj   +1 more source

Primary multiple BRCA associated breast cancer and ovarian cancer (clinical case)

Медицинский совет, 2020
Introduction. The study of mutation in BRCA1/2 genes was first initiated in the USA and Europe, and later in Russia. Statistics indicate that women with the BRCA1/BRCA2 mutation have a higher risk of breast and/or ovarian cancer than the general ...
I. B. Kononenko, A. V. Snegovoy, Y. A. Bozhchenko, D. N. Kravchenko, Vladimir Yu. Selchuk, O. V. Palchinskaia   +5 more
doaj   +1 more source

Triple-negative breast cancer arising in a fibroadenoma in BRCA 1 mutated patient

Journal of Medical Ultrasound, 2023
We describe the case of a 35-year-old woman who comes to our institute with a palpable lump on her left breast. Clinically the mass was mobile, nontender and with no nipple discharge. Sonography revealed a circumscribed, oval-shaped, and hypoechoic mass,
Nicole Brunetti, Irene Valente, Francesca Pitto, Massimo Calabrese   +3 more
doaj   +1 more source

BRCA mutations and reproduction [PDF]

Fertility and Sterility, 2018
Deleterious mutations in BRCA1 or BRCA2 genes have long been recognized as independent risk factors, mostly for breast and ovarian cancer. Numerous studies have evaluated the molecular processes involving these genes, the pathophysiology of BRCAness, follow up options and modes of prophylaxis.
Hagit, Daum, Tamar, Peretz, Neri, Laufer
openaire   +2 more sources

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis

Journal of Obstetrics and Gynaecology, 2023
Without taking into account existing biomarkers like genetic mutations (BRCA mutation, Homologous recombination deficiency) with advanced ovarian cancer (OC), the overall survival (OS), progress-free survival (PFS) of the aggregate all groups that have ...
Yanhui Li
doaj   +1 more source

Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study

European Journal of Breast Health, 2021
Objective:This study aimed to determine the differences in clinicopathological features of Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer susceptibility genes (BRCA1/2) .Materials and Methods:This study ...
Muhammed Mustafa Atcı, Çağlayan Geredeli, Seval Ay, Abdullah Sakin, Biray Ertürk, Şaban Seçmeler, Serdar Arıcı, Ruhper Çekin, Nurgül Yaşar, Orçun Can, Şener Cihan, Mahmut Gümüş   +11 more
doaj   +1 more source

Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program

Медицинский совет, 2022
Introduction. Olaparib is the only PARP inhibitor approved in Russia for the maintenance therapy for BRCA-positive ovarian cancer after frontline chemotherapy. We conducted a real-world analysis of olaparib efficacy and safety for this indication.Aim. To
A. A. Rumyantsev, A. S. Tyulyandina, I. A. Pokataev, E. R. Israelyan, M. Е. Abramov, H. N. Lud, S. A. Tyulyandin   +6 more
doaj   +1 more source

BRCA Mutations and Fertility Preservation [PDF]

International Journal of Molecular Sciences, 2023
Hereditary cancers mostly affect the adolescent and young adult population (AYA) at reproductive age. Mutations in BReast CAncer (BRCA) genes are responsible for the majority of cases of hereditary breast and ovarian cancer. BRCA1 and BRCA2 act as tumor suppressor genes as they are key regulators of DNA repair through homologous recombination. Evidence
Joana Dias Nunes, Isabelle Demeestere, Melody Devos   +2 more
openaire   +2 more sources